Marcus Björnsson, Ph.D.

Principal Director, MIDD Consultant

Portrait-of-Marcus-Bjornsson-Pharmetheus-1

Bio

  • Joined Pharmetheus in 2014, actively working in client projects and serving as Project Portfolio Team Leader
  • Expertise includes pharmacometrics, clinical pharmacology, and pediatrics in therapeutic areas such as neuroscience and orphan indications
  • Previously worked as Neuroscience Therapy Area Pharmacometrics Expert at AstraZeneca R&D, Sweden, where he had strategic and scientific accountability for pharmacometric activities within the neuroscience therapy area, as Clinical Pharmacokineticist, Senior Research Scientist, and Senior Pharmacometrician at AstraZeneca R&D, Sweden, and Research Scientist at Astra Pain Control, Sweden
  • M.Sc. in Pharmaceutical Sciences (1999) and Ph.D. in Pharmacokinetics and Drug Therapy (2013) from Uppsala University, Sweden
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Quantitative Relationship Between Tominersen Concentrations in Cerebrospinal Fluid and Biomarker Changes in Huntington’s Disease PatientsPharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorderDevelopment of a population pharmacokinetic model to characterize the pharmacokinetics of intrathecally administered tominersen in cerebrospinal fluid and plasmaPopulation Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use DisorderA Bolus and Bolus Followed by Infusion Study of AZD3043, an Investigational Intravenous Drug for Sedation and Anesthesia: Safety and Pharmacodynamics in Healthy Male and Female Volunteers